Newron starts PD Phase III

Newron (Milan, Italy) started an international Phase III trial of safinamide as an add-on to dopamine agonist therapy in 240 patients with early stage Parkinson's disease (PD). The primary endpoint is the change from baseline in mean value of United Parkinson's Disease Rating Scale (UPDRS) Section III (motor score) and Clinical Global Improvement (CGI). ...